What are the causes of reduced ejaculatory force and how can it be restored?

Reduced Ejaculatory Force: Causes and Restoration

Reduced ejaculatory force is most commonly caused by urethral stricture, bulbar urethroplasty complications, medications (especially SSRIs and antipsychotics), testosterone deficiency, or neurologic dysfunction affecting the sympathetic/somatic pathways—and restoration requires addressing the underlying cause through medication adjustment, testosterone replacement when indicated, behavioral modifications to increase arousal, or off-label sympathomimetic agents, with urethral stricture requiring surgical intervention.

Primary Causes of Reduced Ejaculatory Force

Anatomic and Surgical Causes

• Urethral stricture directly causes decreased ejaculatory force as a presenting symptom, along with decreased urinary stream and incomplete bladder emptying 1
• Up to 21% of men experience decreased ejaculatory force following bulbar urethroplasty, often accompanied by semen pooling, ejaculatory discomfort, and decreased semen volume 1
• Ejaculatory duct obstruction or congenital bilateral absence of the vas deferens causes low ejaculate volume (<1.4 mL) with acidic pH, though this affects volume more than force 2

Medication-Induced Dysfunction

• SSRIs (paroxetine, sertraline, fluoxetine, citalopram) cause dose-dependent delayed ejaculation and orgasmic dysfunction that can manifest as reduced force 2
• Antipsychotics and antihypertensives contribute to delayed ejaculation/anorgasmia and should be replaced, dose-adjusted, or staged for cessation 3
• Tricyclic antidepressants (clomipramine) similarly prolong ejaculatory latency 2

Hormonal Causes

• Progressively lower serum testosterone correlates with increased symptoms of delayed ejaculation and anorgasmia, including reduced force 3
• Androgen deficiency impairs seminal vesicle secretion and the entire ejaculatory chain from libido through ejaculation 4

Neurologic and Physiologic Mechanisms

• Ejaculation requires coordinated T9-L2 sympathetic stimulation (for seminal vesicle contraction and bladder neck closure) and S2-S3 somatic stimulation (for expulsion from the urethral bulb) 4
• The lumbar spinothalamic (LSt) cells in the L3-L4 spinal segment serve as the spinal ejaculation generator, and dysfunction at this level impairs ejaculatory force 5
• Inadequate arousal reduces ejaculatory function through psychosexual mechanisms 3

Cancer Treatment Sequelae

• Colorectal cancer survivors experience ejaculatory dysfunction in 45-75% of cases, and prostate cancer survivors in up to 90%, with presentations including decreased intensity and force 1
• Radiation and surgery damage autonomic nerves and blood vessels, causing both erectile and ejaculatory dysfunction 1

Restoration Strategies: A Stepwise Approach

Step 1: Address Reversible Causes First

Medication Review and Adjustment

• Replace, adjust dosage, or implement staged cessation of SSRIs, antipsychotics, and antihypertensives contributing to the dysfunction 3
• This is the lowest-risk intervention and should be attempted before other treatments 3

Hormonal Evaluation and Replacement

• Check morning testosterone levels in all men with reduced ejaculatory force 3
• Offer testosterone replacement therapy per AUA guidelines for men with biochemically low testosterone and symptoms 3
• Testosterone therapy relieves ejaculatory dysfunction in men with hypogonadism 1
• Caution: Do not prescribe testosterone to men actively trying to conceive, as it suppresses sperm production 1

Treat Comorbid Erectile Dysfunction

• Treat erectile dysfunction FIRST according to AUA guidelines, as ED and ejaculatory dysfunction share common risk factors and chronology matters for treatment sequencing 3
• PDE5 inhibitors (sildenafil, tadalafil, vardenafil) improve ED and are well-tolerated in cancer survivors 1
• Start conservatively with on-demand dosing and titrate to maximum dose as needed, or consider daily low-dose therapy 1

Step 2: Behavioral and Psychological Interventions

Arousal Enhancement (First-Line for Primary Dysfunction)

• Modify sexual positions or practices to increase arousal, as adequate arousal is essential for optimal ejaculatory function 3
• Incorporate alternative sexual practices, scripts, and sexual enhancement devices to increase physical and psychological arousal 3
• Include sexual partners in decision-making whenever possible to optimize outcomes 3

Psychological Assessment

• Assess for history of sexual abuse, decreased emotional intimacy, relationship conflict, depression, and mood disorders—all of which impact arousal and orgasmic capacity 3
• Refer to psychotherapy, sexual/couples counseling, or sexual health specialists when appropriate 1

Step 3: Surgical Management for Anatomic Causes

Urethral Stricture Treatment

• Provide appropriate preoperative antibiotics guided by urine cultures to reduce surgical site infections 1
• Surgical options include direct visual internal urethrotomy (DVIU) or open urethral reconstruction (urethroplasty) depending on stricture characteristics 1
• Place urinary catheter postoperatively to divert urine from the intervention site 1
• Perform retrograde urethrogram (RUG) or voiding cystourethrogram (VCUG) 2-3 weeks post-reconstruction to assess healing 1
• Note: Ejaculatory dysfunction after bulbar urethroplasty may resolve over time but affects up to 21% of men 1

Step 4: Pharmacological Options (All Off-Label)

Sympathomimetic Agents

• Consider pseudoephedrine 60-120 mg, ephedrine 15-60 mg, or midodrine 5-40 mg on an individualized basis with appropriate counseling about weak evidence and off-label use 3
• These agents enhance sympathetic stimulation of the ejaculatory reflex 3

Alternative Pharmacological Agents

• Oxytocin 24 IU intranasal/sublingual, bethanecol 20 mg daily, yohimbine 5.4 mg three times daily, cabergoline 0.25-2 mg twice weekly, or imipramine 25-75 mg daily may be considered 3
• All pharmacotherapy is off-label with weak evidence, and patients must understand potential for known and unknown side effects 3

Critical Caveats and Pitfalls

Diagnostic Considerations

• Differentiate true reduced force from other ejaculatory dysfunctions (delayed orgasm, reduced volume, retrograde ejaculation) through comprehensive sexual history 2
• When retrograde ejaculation is suspected, perform post-ejaculatory urinalysis to detect sperm in urine 2
• Focused physical examination should evaluate testicular size, epididymal consistency, and presence of vas deferens to exclude anatomic obstruction 2

Treatment Principles

• No FDA-approved treatments exist for ejaculatory dysfunction; all pharmacotherapy is off-label 3
• Patient and partner satisfaction is the primary target outcome, not arbitrary physiological measures 3
• Orgasm and ejaculation are distinct from erection and can be impaired independently—20% of diabetic men with ED experience orgasmic dysfunction separately 3
• Erectile dysfunction as measured by IIEF may occur transiently after urethroplasty but typically resolves by six months postoperatively 1

Contraindications

• PDE5 inhibitors are contraindicated with oral nitrates due to dangerous blood pressure decreases 1
• Testosterone therapy should not be used in prostate cancer on active surveillance or androgen deprivation therapy 1